Next earnings date: 4 Nov 2025

Teva Pharmaceutical Industries Limited – NYSE:TEVA

Add to watchlist

$17.5

-5.27

-23.14%

Market closed

Open in 3 days

+31.77%

month

+31.77%

quarter

+116.24%

year

Market Cap	24.84B
Enterprise value	29.27B

P/E	-4.43
EV/Sales	1.96
EV/EBITDA	-24.11
Price/Sales	0.70
Price/Book	1.20
PEG ratio	N/A
EPS	-0.40

Revenue	16.01B
EBITDA	4.40B
Income	-493M
Revenue Q/Q	4.67%
Revenue Y/Y	7.31%

Profit margin	-15.77%
Oper. margin	-14.06%
Gross margin	46.72%
EBIT margin	-14.06%
EBITDA margin	27.49%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Teva Pharmaceutical Industries Limited Stock Forecast

M Q Y

Last Year

$24.86

Potential upside: 42.04%

Analysts Price target
Financials & Ratios estimates

Teva Pharmaceutical Industries Limited (NYSE:TEVA): Profit margin
Jun 2023	3.87B	-863M	-22.25%
Sep 2023	3.85B	80M	2.08%
Dec 2023	4.45B	429M	9.63%
Mar 2024	3.83B	-139M	-3.63%

Teva Pharmaceutical Industries Limited (NYSE:TEVA): Earnings per share (EPS)
2024-11-06	0.65	0.69

Teva Pharmaceutical Industries Limited (NYSE:TEVA): Payout ratio
Payout ratio	0%

Teva Pharmaceutical Industries Limited (NYSE:TEVA): Dividend Yield
2019	0.49%
2020
2021
2022
2023

Teva Pharmaceutical Industries Limited (NYSE:TEVA): Debt to assets
Jun 2023	43095000000	35.38B	82.11%
Sep 2023	42088000000	34.57B	82.15%
Dec 2023	43479000000	35.35B	81.31%
Mar 2024	42773000000	35.23B	82.37%

Teva Pharmaceutical Industries Limited (NYSE:TEVA): Cash Flow
Jun 2023	324M	302M	-55M
Sep 2023	5M	184M	-576M
Dec 2023	1.18B	301M	-576M
Mar 2024	171M	-215M	-87M

Teva Pharmaceutical Industries Limited alternative data

Teva Pharmaceutical Industries Limited
Employees

Teva Pharmaceutical Industries Limited (NYSE:TEVA): Employee count
Aug 2023	34,004
Sep 2023	34,004
Oct 2023	34,004
Nov 2023	34,004
Dec 2023	34,004
Jan 2024	34,004
Feb 2024	37,000
Mar 2024	35,001
Apr 2024	35,001
May 2024	35,001
Jun 2024	35,001
Jul 2024	35,001

Teva Pharmaceutical Industries Limited
Hedge Funds Holdings Q1 2022

46.39% +0.84%

of TEVA is owned by hedge funds

417 -9

hedge funds hold TEVA stock

513.53M +8.38M

shares is hold by hedge funds

TEVA hedge funds holdings changes

Teva Pharmaceutical Industries Limited
Insider Trading

Teva Pharmaceutical Industries Limited (NYSE:TEVA): Insider trades (number of shares)
Period	Buy	Sel
Feb 2024	0	311337
Mar 2024	0	303756
May 2024	0	43354
Jun 2024	0	519000
Aug 2024	0	172605
Nov 2024	0	19388
Dec 2024	0	286000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	20 Dec 2024	MIGNONE ROBERTO director director	Ordinary Shares	286,000	$22.01	$6,294,002
Option	20 Nov 2024	FOX CHRISTINE officer: EVP, Head of U.S. Commercial officer: EVP, Head of U.S. Comm..	Restricted Share Units	63,492	N/A	N/A
Option	20 Nov 2024	FOX CHRISTINE officer: EVP, Head of U.S. Commercial officer: EVP, Head of U.S. Comm..	Ordinary Shares	63,492	N/A	N/A
Sale	20 Nov 2024	FOX CHRISTINE officer: EVP, Head of U.S. Commercial officer: EVP, Head of U.S. Comm..	Ordinary Shares	19,388	$16.87	$327,095
Option	2 Sep 2024	SHALEV VARDA director director	Ordinary Shares	12,872	N/A	N/A
Option	2 Sep 2024	SHALEV VARDA director director	Restricted Share Units	12,872	N/A	N/A
Sale	12 Aug 2024	DANIELL RICHARD officer: Exec. VP, European Commercial officer: Exec. VP, European Com..	Ordinary Shares	98,943	$17.3	$1,711,417
Option	9 Aug 2024	GRANT ANGUS officer: EVP, Business Development officer: EVP, Business Developm..	Restricted Share Units	12,913	N/A	N/A
Option	9 Aug 2024	GRANT ANGUS officer: EVP, Business Development officer: EVP, Business Developm..	Ordinary Shares	12,913	N/A	N/A
Sale	9 Aug 2024	GRANT ANGUS officer: EVP, Business Development officer: EVP, Business Developm..	Ordinary Shares	4,065	$17.28	$70,243

TEVA insider trading transactions

Teva Pharmaceutical Industries Limited
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 8 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 31 Jan 2024	Q4 2023 Earnings Call Transcript
Q3 2023 8 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 2 Aug 2023	Q2 2023 Earnings Call Transcript

TEVA earnings call transcripts

Teva Pharmaceutical Industries Limited
Executives

Insider	Age	Compensation
Mr. Kare Schultz (1961) Pres, Chief Executive Officer & Director	64	$5,720,000
Dr. Hafrun Fridriksdottir (1962) Executive Vice President of Global R&D	63	$2,290,000
Mr. Eric Drape (1962) Executive Vice President of Global Operations	63	$2,050,000
Mr. Eliyahu Sharon Kalif (1973) Executive Vice President & Chief Financial Officer	52	$1,770,000

Teva Pharmaceutical Industries Limited
Latest News

Monday, 23 December 2024
16:30	Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference	globenewswire.com
Friday, 20 December 2024
16:30	Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025	globenewswire.com
Wednesday, 18 December 2024
14:29	Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases	benzinga.com
09:25	SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study	zacks.com
07:41	Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength?	zacks.com
04:32	TEVA stock soars 26%: What's going on with Teva Pharmaceuticals?	invezz.com
Tuesday, 17 December 2024
16:50	Overlooked Stock: TEVA	youtube.com
14:25	Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's	investopedia.com
11:51	Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment	wsj.com
10:24	2 Pharma Stocks to Watch: Pfizer, Teva Pharmaceutical	schaeffersresearch.com
09:16	Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?	benzinga.com
07:35	Teva, Sanofi say drug to treat IBD met primary targets	reuters.com
07:30	Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease	globenewswire.com
Friday, 6 December 2024
08:00	Can Teva Return To All-Time Highs?	seekingalpha.com
Thursday, 5 December 2024
18:39	Pharma firm Teva to divest its business venture in Japan	reuters.com
18:00	Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan	globenewswire.com
13:23	Teva Pharmaceutical Industries Limited (TEVA) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript	seekingalpha.com
Wednesday, 4 December 2024
02:00	Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial	globenewswire.com
Thursday, 28 November 2024
16:01	TEVA Stock Down 10% in a Month: Should You Buy the Dip?	zacks.com
Wednesday, 27 November 2024
08:30	2 Generic Drug Stocks Ready to Surge in 2025	marketbeat.com
Monday, 25 November 2024
18:00	Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference	globenewswire.com
Tuesday, 19 November 2024
10:25	Teva Pharmaceutical Industries Limited (TEVA) Jefferies London Healthcare Conference (Transcript)	seekingalpha.com
Friday, 8 November 2024
16:30	Teva to Present at the Jefferies London Healthcare Conference	globenewswire.com
10:46	Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?	zacks.com
Thursday, 7 November 2024
09:50	TEVA Stock Down 7% Despite Q3 Earnings & Sales Beat, Guidance Increase	zacks.com
Wednesday, 6 November 2024
11:42	Teva Pharmaceutical Industries Limited (TEVA) Q3 2024 Earnings Call Transcript	seekingalpha.com
10:35	Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say	zacks.com
10:06	Teva Pharm CEO says will work productively with Trump administration	reuters.com
07:27	Teva Pharmaceutical third-quarter profit, revenue top estimates	reuters.com
07:00	Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS	globenewswire.com

Ideas & Opinions

Seeking Alpha 31 Jul 2025

Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside
Seeking Alpha 18 Jun 2025

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward
Seeking Alpha 27 May 2025

Bristol-Myers Squibb At ASCO 2025: A Resilient Play Amid Market Turbulence
Seeking Alpha 25 May 2025

Why AstraZeneca May Be 2025's Most Underrated Pharma Stock
Seeking Alpha 23 May 2025

Why Investors Should Watch Teva Despite Regional Risks
Seeking Alpha 16 May 2025

Pfizer's Turnaround Story Is Stronger Than You Think
Seeking Alpha 28 Apr 2025

Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results
Seeking Alpha 9 Apr 2025

Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
Seeking Alpha 30 Jan 2025

Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
Seeking Alpha 19 Jan 2025

Top 4 Immunology Stocks Poised For Growth In 2025

Frequently Asked Questions (FAQ)

What's the price of Teva Pharmaceutical Industries Limited stock today?

One share of Teva Pharmaceutical Industries Limited stock can currently be purchased for approximately $17.5.
When is Teva Pharmaceutical Industries Limited's next earnings date?

Teva Pharmaceutical Industries Limited is estimated to report earnings on Tuesday, 4 Nov 2025.
Does Teva Pharmaceutical Industries Limited pay dividends?

No, Teva Pharmaceutical Industries Limited does not pay dividends.
How much money does Teva Pharmaceutical Industries Limited make?

Teva Pharmaceutical Industries Limited has a market capitalization of 24.84B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 6.17% to 15.85B US dollars. Teva Pharmaceutical Industries Limited made a loss 559M US dollars in net income (profit) last year or $0.69 on an earnings per share basis.
What is Teva Pharmaceutical Industries Limited's stock symbol?

Teva Pharmaceutical Industries Limited is traded on the NYSE under the ticker symbol "TEVA".
What is Teva Pharmaceutical Industries Limited's primary industry?

Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
How do i buy shares of Teva Pharmaceutical Industries Limited?

Shares of Teva Pharmaceutical Industries Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Teva Pharmaceutical Industries Limited's key executives?
Teva Pharmaceutical Industries Limited's management team includes the following people:
- Mr. Kare Schultz Pres, Chief Executive Officer & Director(age: 64, pay: $5,720,000)
- Dr. Hafrun Fridriksdottir Executive Vice President of Global R&D(age: 63, pay: $2,290,000)
- Mr. Eric Drape Executive Vice President of Global Operations(age: 63, pay: $2,050,000)
- Mr. Eliyahu Sharon Kalif Executive Vice President & Chief Financial Officer(age: 52, pay: $1,770,000)
How many employees does Teva Pharmaceutical Industries Limited have?

As Jul 2024, Teva Pharmaceutical Industries Limited employs 35,001 workers.
When Teva Pharmaceutical Industries Limited went public?

Teva Pharmaceutical Industries Limited is publicly traded company for more then 43 years since IPO on 16 Feb 1982.
What is Teva Pharmaceutical Industries Limited's official website?

The official website for Teva Pharmaceutical Industries Limited is tevapharm.com.
How can i contact Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited can be reached via phone at +972 3 914 8213.
What is Teva Pharmaceutical Industries Limited stock forecast & price target?

Based on 4 Wall Street analysts` predicted price targets for Teva Pharmaceutical Industries Limited in the last 12 months, the avarage price target is $24.86. The average price target represents a 42.04% change from the last price of $17.5.

Teva Pharmaceutical Industries Limited

tevapharm.com

Exchange:

NYSE

Full time employees:

37,000

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

+972 3 914 8213

124 Dvora Hanevi'a Street
Tel Aviv, 6944020

CIK: 0000818686
ISIN: US8816242098
CUSIP: 881624209